At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 492 enrolled
Drug / intervention
Trifluridine/Tipiracil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)
In Brief
A Phase 3 clinical trial evaluating Trifluridine/Tipiracil and Bevacizumab for Refractory Metastatic Colorectal Cancer. Completed, enrolled 492 participants across 99 sites in 14 countries.
Detailed Summary
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Metastatic Colorectal Cancer
CountriesAustria, Belgium, Brazil, Denmark, France, Germany, Hungary, Italy, Poland, Puerto Rico, Russia, Spain, Ukraine, United States
CollaboratorsInstitut de Recherches Internationales Servier
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedFeb 2021
Primary CompletionJul 2022
Study CompletionSep 2023
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartNov 25, 2020
Primary CompletionJul 19, 2022
Study CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.4 years ago
Interventions
Trifluridine/Tipiracildrug
Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
Bevacizumabdrug
administered every 2 weeks (Day 1 and Day 15)